Phase II study of RCHOP with pegylated liposomal doxorubicin (DRCOP) for patients older than age 60 with untreated diffuse large B-cell lymphoma (DLBCL).
M. A. Rodriguez
No relevant relationships to disclose
J. Durand
No relevant relationships to disclose
A. B. Astrow
No relevant relationships to disclose
M. J. Bury
No relevant relationships to disclose
M. A. Fanale
No relevant relationships to disclose
F. B. Hagemeister
No relevant relationships to disclose
X. Huang
No relevant relationships to disclose
P. McLaughlin
No relevant relationships to disclose
S. S. Neelapu
No relevant relationships to disclose
B. Pro
No relevant relationships to disclose
L. W. Kwak
No relevant relationships to disclose
L. Fayad
No relevant relationships to disclose
J. E. Romaguera
Research Funding - Celgene; Millennium; Wyeth
A. Younes
No relevant relationships to disclose
M. Fisch
No relevant relationships to disclose